secwatch.observer — SEC 8-K summary
======================================

Issuer:     IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
CIK:        0001425205
Form:       8-K
Filed at:   2025-02-10T23:59:59+00:00
Accession:  0001104659-25-010729
Event type: leadership
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iovance appoints Dan Kirby as Chief Commercial Officer to lead Amtagvi launch expansion
--------------------------------------------------------------------------------

- Dan Kirby appointed CCO effective February 10, 2025.
- Kirby brings cell therapy commercial experience from Orca Bio, Omeros, Celgene/BMS, and Juno.
- He will lead U.S. launch growth of Amtagvi and expansion of Proleukin sales.
- Iovance also preparing to enter new international markets.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1425205/000110465925010729/0001104659-25-010729-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1425205/000110465925010729/tm255949d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-010729

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer